Denali Therapeutics Inc. Common Stock
DNLI Real Time Price USDRecent trades of DNLI by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in DNLI holdings by institutional investors
Quarterly net insider trading by DNLI's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
DNLI Estimated quarterly lobbying spending
DNLI Revenue by Segment or Geography
New DNLI patent grants
-
Patent Title: Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof Aug. 05, 2025
-
Patent Title: Compounds, compositions and methods Jul. 15, 2025
-
Patent Title: Lrrk2 inhibitors and methods of making and using thereof Jul. 15, 2025
-
Patent Title: Anti-trem2 antibodies and methods of use thereof Mar. 04, 2025
-
Patent Title: Compounds, compositions and methods Dec. 31, 2024
-
Patent Title: Methods of engineering transferrin receptor binding polypeptides Dec. 10, 2024
-
Patent Title: Compounds, compositions and methods Nov. 12, 2024
-
Patent Title: Kinase inhibitors and uses thereof Oct. 29, 2024
-
Patent Title: Compounds, compositions and methods Sep. 17, 2024
-
Patent Title: Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide Jun. 04, 2024
-
Patent Title: Compounds, compositions and methods Apr. 16, 2024
-
Patent Title: Methods of engineering transferrin receptor binding polypeptides Feb. 27, 2024
-
Patent Title: Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof Jan. 30, 2024
-
Patent Title: Fusion proteins comprising enzyme replacement therapy enzymes Jan. 09, 2024
-
Patent Title: Modulators of eukaryotic initiation factor 2b, compositions and methods Dec. 26, 2023
-
Patent Title: Compounds, compositions and methods Dec. 26, 2023
-
Patent Title: Substituted pyrimidines as lrkk2 inhibitors Dec. 12, 2023
-
Patent Title: Compounds, compositions, and methods Dec. 05, 2023
-
Patent Title: Process for the preparation of pyrimidinyl-4-aminopyrazole compounds Dec. 05, 2023
-
Patent Title: Engineered transferrin receptor binding polypeptides Oct. 24, 2023
-
Patent Title: Anti-bace1 antibodies and methods of use thereof Oct. 03, 2023
-
Patent Title: Engineered polypeptides Aug. 22, 2023
-
Patent Title: Phospho-rab antibodies, assays and methods of use thereof May. 30, 2023
-
Patent Title: Progranulin variants May. 09, 2023
-
Patent Title: Transferrin receptor transgenic models Mar. 28, 2023
-
Patent Title: Compounds, compositions, and methods Feb. 28, 2023
-
Patent Title: Anti-tau antibodies and methods of use thereof Jun. 28, 2022
-
Patent Title: Compounds, compositions and methods Apr. 19, 2022
-
Patent Title: Modulators of eukaryotic initiation factor 2b, compositions and methods Feb. 01, 2022
-
Patent Title: Compound, compositions, and methods Jan. 04, 2022
-
Patent Title: Kinase inhibitors and uses thereof Dec. 21, 2021
-
Patent Title: Compounds, compositions and methods Nov. 16, 2021
-
Patent Title: Anti-trem2 antibodies and methods of use thereof Sep. 21, 2021
-
Patent Title: Compounds, compositions, and methods Sep. 07, 2021
-
Patent Title: Compounds, compositions and methods Jul. 27, 2021
-
Patent Title: Substituted pyrimidines as lrkk2 inhibitors Jun. 08, 2021
-
Patent Title: Fusion proteins comprising enzyme replacement therapy enzymes Dec. 22, 2020
-
Patent Title: Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production Dec. 01, 2020
-
Patent Title: Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk1) Jul. 14, 2020
-
Patent Title: Compounds, compositions, and methods Mar. 17, 2020
-
Patent Title: Engineered polypeptides Oct. 29, 2019
-
Patent Title: Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production Aug. 06, 2019
-
Patent Title: Transferrin receptor transgenic models Dec. 04, 2018
-
Patent Title: Compounds, compositions and methods Nov. 20, 2018
-
Patent Title: Compounds, compositions, and methods Apr. 03, 2018
-
Patent Title: Compounds, compositions and methods Feb. 20, 2018
-
Patent Title: Compounds, compositions and methods Nov. 14, 2017
-
Patent Title: Oxadiazine compounds and methods of use thereof Oct. 31, 2017
-
Patent Title: Fused morpholinopyrimidines and methods of use thereof Sep. 26, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded to DNLI from public contracts
Recent insights relating to DNLI
Recent picks made for DNLI stock on CNBC
ETFs with the largest estimated holdings in DNLI
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $DNLI stock a Buy, Sell, or Hold?
- What is the price target for $DNLI stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $DNLI stock?
- Who owns the most shares of $DNLI stock?
- What funds own $DNLI stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DNLI Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
- Address South San Francisco, CA
- Market Cap 2.6 billion
- Employees 517
- Industrial Classification Biological Products, (No Disgnostic Substances)